Careers  |   Log In  |   Register  |   Welcome Center  |   Follow Us  Facebook  Twitter Google Plus
 
Course List

  • CME Information

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

The intended audience for the activity is pulmonologists and other health care professionals involved in the treatment of patients with idiopathic pulmonary fibrosis (IPF).

Learning Objectives

Upon successful completion of the activity series, participants should be better able to:

  • Assess recent clinical advances regarding the use of available and emerging therapies for the management of IPF.
  • Implement treatment strategies that reflect the most recent clinical data regarding the treatment of IPF.

Overview

Diffuse interstitial lung disease (ILD) is an umbrella term that comprises a broad range of related conditions causing shortness of breath and cough. Idiopathic pulmonary fibrosis (IPF), is a chronic, progressive, fibrotic lung disease of unknown cause and is associated with comorbidities, including pulmonary hypertension. The historical standard of care for IPF is oxygen supplementation, management of comorbidities, and lung transplantation. The therapeutic landscape for IPF management has evolved with the US Food and Drug Administration’s approval of 2 novel therapeutic agents. In these expert interviews, leading clinicians will review guideline updates and strategies for making a diagnosis of IPF, and assess recent clinical advances regarding the use of available and emerging therapies for the management of IPF.

Faculty

Lisa H. Lancaster, MD
Associate Professor
Division of Allergy, Pulmonary, and Critical Care Medicine
Vanderbilt University Medical Center
Nashville, TN

Steven D. Nathan, MD
Medical Director Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Professor of Medicine, Virginia Commonwealth University - Inova Fairfax Campus
Falls Church, VA

Reviewers

Amy L. Olson, MD, MSPH

Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™, 0.25 credits per video. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, December 31, 2016 to December 31, 2017.

How to Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly for each video. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.

Faculty members report the following relationship(s):

Lisa H. Lancaster, MD

Consulting Fees: Boehringer Ingelheim, Genentech, Intermune

Speakers Bureau: Boehringer Ingelheim, Genentech

Contracted Research: Boehringer-Ingelheim, Fibrogen, Gobal Blood Therapeutics, Roche, Stromedix

Steven D. Nathan, MD

Consulting Fees: Boehringer Ingelheim, Genentech

Speakers Bureau: Boehringer Ingelheim, Genentech

Reviewers report the following relationship(s):

Amy L. Olson, MD, MSPH

Speakers Bureau: Boehringer Ingelheim

Non-CME Services Fees: Boehringer Ingelheim, Genentech

Contracted Research: United Therapeutics

Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP

No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Educational Tools

For a full list of all the educational tools available through Vindico Medical Education, please visit www.VindicoCME.com/educationaltools.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicocme.com